Accent Microcell

Why is Accent Microcell Ltd falling/rising?

As of 17-Jun, Accent Microcell Ltd's stock price is declining, currently at 435.30, down 1.03%. The stock has underperformed significantly over the past week, with decreased investor participation and trading activity contributing to its downward trend.

As of 17-Jun, Accent Microcell Ltd's stock price is falling, currently at 435.30, which reflects a decrease of 4.55 or 1.03%. This decline is evident in the stock's performance over the past week, where it has underperformed significantly, showing a drop of 5.56% compared to a 3.75% increase in the Sensex. Additionally, the stock has underperformed its sector today by 1.03%.<BR><BR>Investor participation has also decreased, as indicated by a significant drop in delivery volume, which fell by 70.96% against the 5-day average. This reduction in trading activity suggests a lack of interest or confidence among investors, contributing to the downward pressure on the stock price. While the stock remains above its 100-day and 200-day moving averages, it is below its 5-day, 20-day, and 50-day moving averages, indicating a short-term weakness in price momentum. Overall, these factors collectively explain the current decline in Accent Microcell Ltd's stock price.

Which are the latest news on Accent Microcell?

What does Accent Microcell do?

Accent Microcell Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, recently transitioning to a Public Limited Company. As of March 2023, it reported net sales of 59 Cr and a net profit of 7 Cr, with a market cap of INR 1,140 Cr.

Overview:<BR>Accent Microcell Ltd operates in the Pharmaceuticals & Biotechnology industry and is classified as a Micro Cap company.<BR><BR>History:<BR>The company was originally incorporated on April 10, 2012, as "Accent Microcell Private Limited." It transitioned from a Private Limited Company to a Public Limited Company, changing its name to Accent Microcell Limited, with a fresh Certificate of Incorporation issued on December 23, 2022. The latest quarterly results reported net sales and net profit for March 2023.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 59 Cr (Quarterly Results - Mar 2023)<BR>- Most recent Net Profit: 7 Cr (Quarterly Results - Mar 2023)<BR>- Market-cap value: INR 1,140 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 25.00<BR>- Industry P/E: 34<BR>- Dividend Yield: 0.21%<BR>- Debt Equity: -0.07<BR>- Return on Equity: 15.92%<BR>- Price to Book: 4.14<BR><BR>Contact Details:<BR>Registrar Address: Not available.

How big is Accent Microcell?

As of 10th June, Accent Microcell Ltd has a market capitalization of 1,140.00 Cr, with recent net sales of 58.81 Cr and a net profit of 7.06 Cr for the quarter ending March 2023.

As of 10th June, Accent Microcell Ltd has a market capitalization of 1,140.00 Cr, which classifies it as a Micro Cap company.<BR><BR>In the latest quarter ending March 2023, Accent Microcell reported Net Sales of 58.81 Cr and a Net Profit of 7.06 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, where Shareholder's Funds are valued at 194.79 Cr and Total Assets amount to 228.37 Cr.

Who are the peers of the Accent Microcell?

Peers of Accent Microcell include Jagsonpal Pharma, Syncom Formul., Lincoln Pharma, Bajaj Healthcare, Fermenta Biotec., Themis Medicare, Wanbury, Fredun Pharma, Shukra Pharma, and Bharat Parenter. Accent Microcell leads in 1-year returns at 94.35%, while Bajaj Healthcare has the lowest at -44.16%.

Peers: The peers of Accent Microcell are Jagsonpal Pharma, Syncom Formul., Lincoln Pharma., Bajaj Healthcare, Fermenta Biotec., Themis Medicare, Wanbury, Fredun Pharma, Shukra Pharma, and Bharat Parenter.<BR><BR>Quality Snapshot: Excellent management risk is observed at Jagsonpal Pharma, Syncom Formul., Lincoln Pharma., and Accent Microcell, while Average management risk is found at Bajaj Healthcare, Fermenta Biotec., Themis Medicare, Wanbury, Fredun Pharma, Shukra Pharma, and Bharat Parenter. Growth is rated as Excellent for Fredun Pharma and Shukra Pharma, Good for Accent Microcell and Wanbury, and Below Average for Jagsonpal Pharma, Syncom Formul., Lincoln Pharma., Bajaj Healthcare, Fermenta Biotec., Themis Medicare, and Bharat Parenter. Capital Structure is rated as Excellent for Accent Microcell, Jagsonpal Pharma, Syncom Formul., and Lincoln Pharma., while Below Average is noted for Bajaj Healthcare, Fermenta Biotec., Themis Medicare, Wanbury, and Fredun Pharma, with Average for Bharat Parenter.<BR><BR>Return Snapshot: Accent Microcell has a 1-year return of 94.35%, making it the highest among its peers, while Bajaj Healthcare has the lowest at -44.16%. Accent Microcell's return significantly outperforms all its peers. Additionally, Bajaj Healthcare, Fermenta Biotec., Themis Medicare, Wanbury, and Bharat Parenter all have negative six-month returns.

Is Accent Microcell overvalued or undervalued?

As of November 28, 2025, Accent Microcell is considered fairly valued with a PE ratio of 23.75, an EV to EBITDA of 17.72, and a ROCE of 18.20%, outperforming the Sensex with a year-to-date return of 21.22%.

As of 28 November 2025, the valuation grade for Accent Microcell has moved from very attractive to attractive. The company is currently considered fairly valued. Key ratios include a PE ratio of 23.75, an EV to EBITDA of 17.72, and a ROCE of 18.20%. <BR><BR>In comparison to its peers, Accent Microcell's PE ratio is lower than Sun Pharma's 38.03 and Divi's Lab's 69.12, which are categorized as expensive. However, it is slightly higher than Cipla's 22.71 and Dr. Reddy's Labs' 18.19, both of which are rated attractive. Notably, Accent Microcell has outperformed the Sensex with a year-to-date return of 21.22% compared to the Sensex's 10.82%, reinforcing its valuation story.

Is Accent Microcell technically bullish or bearish?

As of October 16, 2025, Accent Microcell shows a mildly bullish trend supported by daily moving averages and Bollinger Bands, despite some caution from bearish signals in the weekly MACD and KST.

As of 16 October 2025, the technical trend for Accent Microcell has changed from sideways to mildly bullish. The daily moving averages indicate a mildly bullish stance, while the weekly Dow Theory also supports this with a mildly bullish signal. However, the weekly MACD and KST are mildly bearish, which introduces some caution. The Bollinger Bands are bullish on both weekly and monthly time frames, suggesting potential upward momentum. Overall, the current technical stance is mildly bullish, driven primarily by the daily moving averages and Bollinger Bands, despite some bearish signals from the MACD and KST.

How has been the historical performance of Accent Microcell?

Accent Microcell has shown consistent growth over the past four years, with net sales increasing from 165.71 Cr in Mar'22 to 264.58 Cr in Mar'25, and profit after tax rising from 5.89 Cr to 33.06 Cr, reflecting strong financial performance and improved operational efficiency.

Answer:<BR>The historical performance of Accent Microcell shows a consistent growth trend in net sales and profitability over the past four years.<BR><BR>Breakdown:<BR>Accent Microcell's net sales have increased from 165.71 Cr in Mar'22 to 264.58 Cr in Mar'25, reflecting a strong upward trajectory. The total operating income has followed a similar trend, rising from 165.71 Cr in Mar'22 to 264.58 Cr in Mar'25. The company's operating profit (PBDIT) has also seen significant growth, climbing from 14.80 Cr in Mar'22 to 48.32 Cr in Mar'25, with an operating profit margin of 15.84% in Mar'25. Profit before tax has risen from 7.59 Cr in Mar'22 to 43.76 Cr in Mar'25, while profit after tax has increased from 5.89 Cr to 33.06 Cr in the same period, resulting in a PAT margin of 12.5% in Mar'25. The company's total assets have grown from 94.61 Cr in Mar'22 to 228.37 Cr in Mar'25, with total liabilities increasing from 94.61 Cr to 228.37 Cr as well. Cash flow from operating activities has improved significantly, reaching 24.00 Cr in Mar'25, while the net cash inflow has also increased to 2.00 Cr. Overall, Accent Microcell has demonstrated robust financial growth and improved operational efficiency over the years.

Who are the top shareholders of the Accent Microcell?

The top shareholders of Accent Microcell are Nitin Jasvantbhai Patel with 15.59%, Kantilal Pachan Vadia with 9.19%, and individual investors collectively owning 37.49%. There are no pledged promoter holdings, and the company has minimal foreign institutional investment at 0.01%, with no mutual fund holdings.

The top shareholders of Accent Microcell include the promoters, who hold the majority of the shares. The promoter with the highest holding is Nitin Jasvantbhai Patel, with a stake of 15.59%. The highest public shareholder is Kantilal Pachan Vadia, who holds 9.19%. Additionally, individual investors collectively own 37.49% of the company. There are no pledged promoter holdings, and the company is held by one foreign institutional investor (FII) at 0.01%. Mutual funds currently do not hold any shares in Accent Microcell.

When is the next results date for Accent Microcell?

No Upcoming Board Meetings

Has Accent Microcell declared dividend?

Accent Microcell Ltd has declared a 10% dividend, amounting to 1 per share, with an ex-date of September 2, 2024. Despite this declaration, the company's total returns have been negative over various periods, indicating a decline in price performance.

Accent Microcell Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: 02 Sep 24<BR><BR>Dividend Yield: 0.38%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -13.53%, the dividend return was 0%, resulting in a total return of -13.53%.<BR><BR>Over the past year, the price return was -14.81%, the dividend return was 0.34%, leading to a total return of -14.47%.<BR><BR>For the 2-year period, there was no price return, no dividend return, and the total return remained at 0.0%.<BR><BR>In the 3-year period, both the price return and dividend return were 0%, resulting in a total return of 0.0%.<BR><BR>For the 4-year period, there were no changes in price or dividends, maintaining a total return of 0.0%.<BR><BR>In the 5-year period, again, there was no price return or dividend return, keeping the total return at 0.0%.<BR><BR>Overall, while Accent Microcell has declared a dividend, the total returns over various periods indicate a decline in price returns, with limited dividend contributions, suggesting a challenging performance landscape for the company.